Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2) guidelines.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. The modifying role of physical activity in the cross-sectional and longitudinal association of health-related quality of life with physiological functioning-based latent classes and metabolic syndrome.Health and quality of life outcomes · 2020
   Article
2. Does treatment-resistant hypertension exist in children? A review of the evidence.Pediatric nephrology (Berlin, Germany) · 2020
   Review
3. Traditional Uses, Pharmacological Efficacy, and Phytochemistry ofFrontiers in pharmacology · 2018
   Review
4. Influence of ezetimibe on selected parameters of oxidative stress in rat liver subjected to ischemia/reperfusion.Archives of medical science : AMS · 2014
   Article
5. Cardiovascular screening in general practice in a low SES area.BMC family practice · 2012
   Article
6. Antihypertensive treatment, adiponectin and cardiovascular risk.Journal of human hypertension · 2007
   Review
7. Body mass index and blood pressure: where are we now?Journal of human hypertension · 2007
   Article
8. Towards improving the clinical assessment and management of human hypertension: An overview from this Journal.Journal of human hypertension · 2006
   Review
9. Coffee and health: Explaining conflicting results in hypertension.Journal of human hypertension · 2006
   Article
10. Does eplerenone have a future in the management of hypertension in Europe?Journal of human hypertension · 2006
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as